Role of RNA Splicing Mutations in Diffuse Large B Cell Lymphoma

References

• de Leval L, Jaffe ES. Lymphoma classification. Cancer J. 2020;26(3):176–185. doi:10.1097/PPO.0000000000000451
   PubMed Web of Science ®Google Scholar
• Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375–2390. doi:10.1182/blood-2016-01-643569
   PubMed Web of Science ®Google Scholar
• Moghanibashi M, Mohamadynejad P. Splicing in Cancer. hematologica. 2022;14(23):214.
   Google Scholar
• Asmar F, Punj V, Christensen J, et al. Genome-wide profiling identifies a DNA methylation signature that associates with TET2 mutations in diffuse large B-cell lymphoma. Haematologica. 2013;98(12):1912. doi:10.3324/haematol.2013.088740
   PubMed Web of Science ®Google Scholar
• Chapuy B, Stewart C, Dunford AJ, et al. Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat med. 2018;24(5):679–690. doi:10.1038/s41591-018-0016-8
   PubMed Web of Science ®Google Scholar
• Andrades A, Álvarez-Pérez JC, Patiño-Mercau JR, Cuadros M, Baliñas-Gavira C, Medina PP. Recurrent splice site mutations affect key diffuse large B-cell lymphoma genes. Blood. 2022;139(15):2406–2410. doi:10.1182/blood.2021011708
   PubMed Web of Science ®Google Scholar
• Reddy A, Zhang J, Davis NS, et al. Genetic and functional drivers of diffuse large B cell lymphoma. Cell. 2017;171(2):481–94.e15. doi:10.1016/j.cell.2017.09.027
   PubMed Web of Science ®Google Scholar
• Schmitz R, Wright GW, Huang DW, et al. Genetics and pathogenesis of diffuse large B-cell lymphoma. N Engl J Med. 2018;378(15):1396–1407. doi:10.1056/NEJMoa1801445
   PubMed Web of Science ®Google Scholar
• Wang X, Hong Y, Meng S, et al. A novel immune-related epigenetic signature based on the transcriptome for predicting the prognosis and therapeutic response of patients with diffuse large B-cell lymphoma. Clin Immun. 2022;243:109105. doi:10.1016/j.clim.2022.109105
   PubMed Web of Science ®Google Scholar
• Zhang S, Zhang T, Liu H, et al. Tracking the evolution of untreated high‐intermediate/high‐risk diffuse large B‐cell lymphoma by circulating tumour DNA. Br J Haematol. 2022;196(3):617–628. doi:10.1111/bjh.17894
   PubMed Web of Science ®Google Scholar
• Zhang H, Lu Y, Zhang T, et al. PIM1 genetic alterations associated with distinct molecular profiles, phenotypes and drug responses in diffuse large B‐cell lymphoma. Clin Transl Med. 2022;12(4). doi:10.1002/ctm2.808
   Web of Science ®Google Scholar
• Hahn CN, Venugopal P, Scott HS, Hiwase DK. Splice factor mutations and alternative splicing as drivers of hematopoietic malignancy. Immunol Rev. 2015;263(1):257–278. doi:10.1111/imr.12241
   PubMed Web of Science ®Google Scholar
• Ebert B, Bernard OA. Mutations in RNA splicing machinery in human cancers. N Engl J Med. 2011;365(26):2534–2535. doi:10.1056/NEJMe1111584
   PubMed Web of Science ®Google Scholar
• Saez B, Walter MJ, Graubert TA. Splicing factor gene mutations in hematologic malignancies. Blood. 2017;129(10):1260–1269. doi:10.1182/blood-2016-10-692400
   PubMed Web of Science ®Google Scholar
• Akinyi MV, Frilander MJ. At the intersection of major and minor spliceosomes: crosstalk mechanisms and their impact on gene expression. Front Genet. 2021;12:700744. doi:10.3389/fgene.2021.700744
   PubMed Web of Science ®Google Scholar
• Chen W, Moore MJ. Spliceosomes. Curr. 2015;25(5):R181–R183. doi:10.1016/j.cub.2014.11.059
   Google Scholar
• Kitamura K, Nimura K. Regulation of RNA splicing: aberrant splicing regulation and therapeutic targets in cancer. Cells. 2021;10(4):923. doi:10.3390/cells10040923
   PubMed Web of Science ®Google Scholar
• Olthof AM, White AK, Mieruszynski S, et al. Disruption of exon-bridging interactions between the minor and major spliceosomes results in alternative splicing around minor introns. Nucleic Acids Res. 2021;49(6):3524–3545. doi:10.1093/nar/gkab118
   PubMed Web of Science ®Google Scholar
• Chen S, Benbarche S, Abdel-Wahab O. Splicing factor mutations in hematologic malignancies. Blood. 2021;138(8):599–612. doi:10.1182/blood.2019004260
   PubMed Web of Science ®Google Scholar
• Gurnari C, Pagliuca S, Visconte V. Alternative splicing in myeloid malignancies. Biomedicine. 2021;9(12):1844.
   Google Scholar
• Leivonen S, Taskinen M, Cervera A, et al. Alternative splicing discriminates molecular subtypes and has prognostic impact in diffuse large B-cell lymphoma. Blood Cancer j. 2017;7(8):596. doi:10.1038/bcj.2017.71
   Google Scholar
• Taylor J, Lee SC. Mutations in spliceosome genes and therapeutic opportunities in myeloid malignancies. Genes Chromosom Cancer. 2019;58(12):889–902. doi:10.1002/gcc.22784
   PubMed Web of Science ®Google Scholar
• Ngo VN, Young RM, Schmitz R, et al. Oncogenically active MYD88 mutations in human lymphoma. Nature. 2011;470(7332):115–119. doi:10.1038/nature09671
   PubMed Web of Science ®Google Scholar
• Schneider M, Schneider S, Zühlke‐Jenisch R, et al. Alterations of the CD58 gene in classical Hodgkin lymphoma. Gene Chromosom Cancer. 2015;54(10):638–645. doi:10.1002/gcc.22276
   PubMed Web of Science ®Google Scholar
• Takeuchi T, Yamaguchi M, Kobayashi K, et al. MYD88, CD79B, and CARD11 gene mutations in CD5‐positive diffuse large B‐cell lymphoma. Cancer. 2017;123(7):1166–1173. doi:10.1002/cncr.30404
   PubMed Web of Science ®Google Scholar
• Voropaeva EN, Pospelova TI, Voevoda MI, Maksimov VN, Orlov YL, Seregina OB. Clinical aspects of TP53 gene inactivation in diffuse large B-cell lymphoma. BMC Genom. 2019;12(2):35–44. doi:10.1186/s12920-019-0484-9
   Google Scholar
• Chapuy B, Stewart C, Dunford AJ, et al. Author Correction: molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat med. 2018;24(8):1290–1291. doi:10.1038/s41591-018-0097-4
   PubMedGoogle Scholar
• Wilkinson ME, Charenton C, Nagai K. RNA splicing by the spliceosome. Annu Rev Biochem. 2020;89(1):359–388. doi:10.1146/annurev-biochem-091719-064225
   PubMedGoogle Scholar
• Zhou J, Chng WJ. Aberrant RNA splicing and mutations in spliceosome complex in acute myeloid leukemia. Stem Cell Investig. 2017;4:6. doi:10.21037/sci.2017.01.06
   PubMedGoogle Scholar
• Dobashi A. Molecular pathogenesis of diffuse large B-cell lymphoma. JCEH. 2016;56(2):71–78. doi:10.3960/jslrt.56.71
   Google Scholar
• Jung H, Lee KS, Choi JK. Comprehensive characterisation of intronic mis-splicing mutations in human cancers. Oncogene. 2021;40(7):1347–1361. doi:10.1038/s41388-020-01614-3
   PubMed Web of Science ®Google Scholar
• Yang H, Beutler B, Zhang D. Emerging roles of spliceosome in cancer and immunity. Protein Cell. 2021;13(8):559–579.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Qian J, Gu C, Yang Y. Alternative splicing and cancer: a systematic review. Signal Transduct Target Ther. 2021;6(1):78. doi:10.1038/s41392-021-00486-7
   PubMed Web of Science ®Google Scholar
• Aggarwal V, Das A, Bal A, et al. MYD88, CARD11, and CD79B oncogenic mutations are rare events in the Indian cohort of de novo nodal diffuse large B-cell lymphoma. AIMM. 2019;27(4):311–318. doi:10.1097/PAI.0000000000000585
   Google Scholar
• Caeser R, Di Re M, Krupka JA, et al. Genetic modification of primary human B cells to model high-grade lymphoma. Natcommun. 2019;10(1):1–16.
   Google Scholar
• Baliñas-Gavira C, Rodríguez MI, Andrades A, et al. Frequent mutations in the amino-terminal domain of BCL7A impair its tumor suppressor role in DLBCL. Leukemia. 2020;34(10):2722–2735. doi:10.1038/s41375-020-0919-5
   PubMed Web of Science ®Google Scholar
• Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403(6769):503–511. doi:10.1038/35000501
   PubMed Web of Science ®Google Scholar
• Jallades L, Baseggio L, Sujobert P, et al. Exome sequencing identifies recurrent BCOR alterations and the absence of KLF2, TNFAIP3 and MYD88 mutations in splenic diffuse red pulp small B-cell lymphoma. Haematologica. 2017;102(10):1758–1766. doi:10.3324/haematol.2016.160192
   PubMed Web of Science ®Google Scholar
• Koens L, Zoutman WH, Ngarmlertsirichai P, et al. Nuclear factor-κB pathway-activating gene aberrancies in primary cutaneous large B-cell lymphoma, leg type. J Invest Dermatol. 2014;134(1):290–292. doi:10.1038/jid.2013.265
   PubMed Web of Science ®Google Scholar
• Cardona Gloria Y, Bernhart SH, Fillinger S, et al. Absence of non-canonical, inhibitory MYD88 splice variants in B cell lymphomas correlates with sustained NF-κB signaling. Front Immunol. 2021;12(8):616–651. doi:10.3389/fimmu.2021.616451
   Google Scholar
• Kishimoto T, Ying B-W, Tsuru S, et al. Molecular clock of neutral mutations in a fitness-increasing evolutionary process. PLoS Genet. 2015;11(7):e1005392. doi:10.1371/journal.pgen.1005392
   PubMed Web of Science ®Google Scholar
• Pimentel H, Parra M, Gee S, et al. A dynamic alternative splicing program regulates gene expression during terminal erythropoiesis. Nucleic Acids Res. 2014;42(6):4031–4042. doi:10.1093/nar/gkt1388
   PubMed Web of Science ®Google Scholar
• Turton KB, Annis DS, Rui L, Esnault S, Mosher DF. Ratios of four STAT3 splice variants in human eosinophils and diffuse large B cell lymphoma cells. PLoS One. 2015;10(5):e0127243. doi:10.1371/journal.pone.0127243
   PubMed Web of Science ®Google Scholar
• Zhu F, Wang KB, Rui L. STAT3 activation and oncogenesis in lymphoma. Cancers. 2019;12(1):19. doi:10.3390/cancers12010019
   PubMed Web of Science ®Google Scholar
• Gao J, Sidiropoulou E, Walker I, et al. SGK1 mutations in DLBCL generate hyperstable protein neoisoforms that promote AKT Independence. Blood. 2021;138(11):959–964. doi:10.1182/blood.2020010432
   PubMed Web of Science ®Google Scholar
• Hartmann S, Schuhmacher B, Rausch T, et al. Highly recurrent mutations of SGK1, DUSP2 and JUNB in nodular lymphocyte predominant Hodgkin lymphoma. Leukemia. 2016;30(4):844–853. doi:10.1038/leu.2015.328
   PubMed Web of Science ®Google Scholar
• Pasqualucci L, Compagno M, Houldsworth J, et al. Inactivation of the PRDM1/BLIMP1 gene in diffuse large B cell lymphoma. JEM. 2006;203(2):311–317. doi:10.1084/jem.20052204
   PubMed Web of Science ®Google Scholar
• Mandelbaum J, Bhagat G, Tang H, et al. BLIMP1 is a tumor suppressor gene frequently disrupted in activated B cell-like diffuse large B cell lymphoma. Cancer Cell. 2010;18(6):568–579. doi:10.1016/j.ccr.2010.10.030
   PubMed Web of Science ®Google Scholar
• Xu-Monette ZY, Medeiros LJ, Li Y, et al. Dysfunction of the TP53 tumor suppressor gene in lymphoid malignancies. Blood. 2012;119(16):3668–3683. doi:10.1182/blood-2011-11-366062
   PubMed Web of Science ®Google Scholar
• Zlamalikova L, Moulis M, Ravcukova B, et al. Complex analysis of the TP53 tumor suppressor in mantle cell and diffuse large B-cell lymphomas. Oncol Rep. 2017;38(4):2535–2542. doi:10.3892/or.2017.5891
   PubMed Web of Science ®Google Scholar
• De Miranda NF, Georgiou K, Chen L, et al. Exome sequencing reveals novel mutation targets in diffuse large B-cell lymphomas derived from Chinese patients. Blood. 2014;124(16):2544–2553. doi:10.1182/blood-2013-12-546309
   PubMed Web of Science ®Google Scholar
• Hegde VV. Zinc Finger Protein 36L1 (ZFP36L1): Gene Expression, Regulation and Interactions with Immune Receptors in Human Tumour Cells. India: University of Essex; 2020.
   Google Scholar
• Oliveira C, Faoro H, Alves LR, Goldenberg S. RNA-binding proteins and their role in the regulation of gene expression in Trypanosoma cruzi and Saccharomyces cerevisiae. Genet Mol Biol. 2017;40(12):22–30. doi:10.1590/1678-4685-gmb-2016-0258
   PubMedGoogle Scholar
• Jespersen DS, Schönherz AA, Due H, Bøgsted M, Sondergaard TE, Dybkær K. Expression of NOTCH3 exon 16 differentiates Diffuse Large B-cell Lymphoma into molecular subtypes and is associated with prognosis. Sci Rep. 2019;9(1):335. doi:10.1038/s41598-018-36680-x
   PubMedGoogle Scholar
• Nowell CS, Radtke F. Notch as a tumour suppressor. Nat Rev Cancer. 2017;17(3):145–159. doi:10.1038/nrc.2016.145
   PubMed Web of Science ®Google Scholar
• Zhang R, Lin P, Yang X, et al. Survival associated alternative splicing events in diffuse large B-cell lymphoma. Am J Transl Res. 2018;10(8):2636.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Dong W, Wang J, Cai J, Wang Z. Human omental adipose-derived mesenchymal stem cell-conditioned medium alters the proteomic profile of epithelial ovarian cancer cell lines in vitro. OncoTargets Ther. 2017;10(18):1655. doi:10.2147/OTT.S129502
   PubMedGoogle Scholar
• Fujimoto A, Okada Y, Boroevich KA, Tsunoda T, Taniguchi H, Nakagawa H. Systematic analysis of mutation distribution in three dimensional protein structures identifies cancer driver genes. Sci Rep. 2016;6(1):1–9. doi:10.1038/srep26483
   PubMedGoogle Scholar
• Challa-Malladi M, Lieu YK, Califano O, et al. Combined genetic inactivation of β2-Microglobulin and CD58 reveals frequent escape from immune recognition in diffuse large B cell lymphoma. Cancer Cell. 2011;20(6):728–740. doi:10.1016/j.ccr.2011.11.006
   PubMed Web of Science ®Google Scholar
• Li Q, Ma L, Wu Z, et al. Zinc finger E‑box binding homeobox 2 functions as an oncogene in human laryngeal squamous cell carcinoma. Mol Med Rep. 2019;19(6):4545–4552. doi:10.3892/mmr.2019.10126
   PubMed Web of Science ®Google Scholar
• Schmidt A, Schmitz R, Giefing M, et al. Rare occurrence of biallelic CYLD gene mutations in classical Hodgkin lymphoma. Genes Chromosom Cancer. 2010;49(9):803–809. doi:10.1002/gcc.20789
   PubMed Web of Science ®Google Scholar
• Xu X, Wei T, Zhong W, et al. Down-regulation of cylindromatosis protein phosphorylation by BTK inhibitor promotes apoptosis of non-GCB-diffuse large B-cell lymphoma. Cancer Cell Int. 2021;21(1):195. doi:10.1186/s12935-021-01891-2
   PubMed Web of Science ®Google Scholar
• Zahn M, Kaluszniak B, Möller P, Marienfeld R. The PTP1B mutant PTP1B∆ 2–4 is a positive regulator of the JAK/STAT signalling pathway in Hodgkin lymphoma. J Carcinog. 2021;42(4):517–527. doi:10.1093/carcin/bgaa144
   Google Scholar
• Zahn M, Marienfeld R, Melzner I, et al. A novel PTPN1 splice variant upregulates JAK/STAT activity in classical Hodgkin lymphoma cells. Blood. 2017;129(11):1480–1490. doi:10.1182/blood-2016-06-720516
   PubMed Web of Science ®Google Scholar
• Walker MP, Stopford CM, Cederlund M, et al. FOXP1 potentiates Wnt/β-catenin signaling in diffuse large B cell lymphoma. Sci.Signal. 2015;8(362):ra12. doi:10.1126/scisignal.2005654
   PubMed Web of Science ®Google Scholar
• Nutt SL, Kee BL. The transcriptional regulation of B cell lineage commitment. Immunity. 2007;26(6):715–725. doi:10.1016/j.immuni.2007.05.010
   PubMed Web of Science ®Google Scholar
• Møller MB, Kania P, Ino Y, et al. Frequent disruption of the RB1 pathway in diffuse large B cell lymphoma: prognostic significance of E2F-1 and p16INK4A. Leukemia. 2000;14(5):898–904. doi:10.1038/sj.leu.2401761
   PubMed Web of Science ®Google Scholar
• Alvarado Y, Giles FJ, Swords RT. The PIM kinases in hematological cancers. Expert Rev Hematol. 2012;5(1):81–96. doi:10.1586/ehm.11.69
   PubMed Web of Science ®Google Scholar
• de Miranda NF, Peng R, Georgiou K, et al. DNA repair genes are selectively mutated in diffuse large B cell lymphomas. J Exp Med J EXP MED. 2013;210(9):1729–1742. doi:10.1084/jem.20122842
   PubMed Web of Science ®Google Scholar
• Elfrink S, de Winde CM, van den Brand M, et al. High frequency of inactivating tetraspanin C D37 mutations in diffuse large B-cell lymphoma at immune-privileged sites. Blood. 2019;134(12):946–950. doi:10.1182/blood.2019001185
   PubMedGoogle Scholar
• Fan Z, Pei R, Sha K, Chen L, Wang T, Lu Y. Comprehensive characterization of driver genes in diffuse large B cell lymphoma. Oncol Lett. 2020;20(1):382–390. doi:10.3892/ol.2020.11552
   PubMed Web of Science ®Google Scholar
• Krysiak K, Gomez F, White BS, et al. Recurrent somatic mutations affecting B-cell receptor signaling pathway genes in follicular lymphoma. Blood. 2017;129(4):473–483. doi:10.1182/blood-2016-07-729954
   PubMed Web of Science ®Google Scholar
• Guo B, Huang Y, Duan Y, Liao C, Cen H. SGK1 mutation status can further stratify patients with germinal center B‐cell‐like diffuse large B‐cell lymphoma into different prognostic subgroups. Cancer Med. 2022;11(5):1281–1291. doi:10.1002/cam4.4550
   PubMed Web of Science ®Google Scholar
• Gribben JG. The sequence of events in diffuse large B-cell lymphoma. Blood. 2013;122(7):1097–1098. doi:10.1182/blood-2013-06-506089
   PubMed Web of Science ®Google Scholar
• Zhang J, Gu Y, Chen B. Drug-resistance mechanism and new targeted drugs and treatments of relapse and refractory DLBCL. Cancer Manag Res. 2023;245–255. doi:10.2147/CMAR.S400013
   PubMed Web of Science ®Google Scholar
• Vaqué JP, Martínez N, Batlle-López A, et al. B-cell lymphoma mutations: improving diagnostics and enabling targeted therapies. Haematologica. 2014;99(2):222–231. doi:10.3324/haematol.2013.096248
   PubMed Web of Science ®Google Scholar
• Shen R, Fu D, Dong L, et al. Simplified algorithm for genetic subtyping in diffuse large B-cell lymphoma. Signal Transduct Target Ther. 2023;8(1):145. doi:10.1038/s41392-023-01358-y
   PubMed Web of Science ®Google Scholar
• Xu-Monette ZY, Wu L, Visco C, et al. Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study. Blood. 2012;120(19):3986–3996. doi:10.1182/blood-2012-05-433334
   PubMed Web of Science ®Google Scholar
• Kusowska A, Kubacz M, Krawczyk M, Slusarczyk A, Winiarska M, Bobrowicz M. Molecular aspects of resistance to immunotherapies advances in understanding and management of diffuse large B-cell lymphoma. Int J Mol Sci. 2022;23(3):1501. doi:10.3390/ijms23031501
   PubMed Web of Science ®Google Scholar
• Wilson WH, Young RM, Schmitz R, et al. Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma. Nat.Med. 2015;21(8):922–926. doi:10.1038/nm.3884
   PubMed Web of Science ®Google Scholar
• Yu H, Sotillo E, Harrington C, et al. Repeated loss of target surface antigen after immunotherapy in primary mediastinal large B cell lymphoma. Am J Hematol. 2017;92(1):E11. doi:10.1002/ajh.24594
   PubMed Web of Science ®Google Scholar
• Sciarrillo R, Wojtuszkiewicz A, Assaraf YG, et al. The role of alternative splicing in cancer: from oncogenesis to drug resistance. Drug Resist Updat. 2020;53:100728. doi:10.1016/j.drup.2020.100728
   PubMed Web of Science ®Google Scholar
• Danilov AV, Magagnoli M, Matasar MJ. Translating the biology of diffuse large B-cell lymphoma into treatment. Oncologist. 2022;27(1):57–66. doi:10.1093/oncolo/oyab004
   PubMed Web of Science ®Google Scholar